Quick Answer
Cullinan Therapeutics, Inc. reported Research And Development Expense of $187.40 million for the year ending 2025.
- Cullinan Therapeutics, Inc. showed an increase of +31.1% in Research And Development Expense from 2024 to 2025.
- This data is from Cullinan Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $4.17 million | Q2 2020: $12.50 million | Q3 2020: $9.91 million | Q1 2021: $12.42 million | Q2 2021: $11.78 million | Q3 2021: $12.68 million | Q1 2022: $24.54 million | Q2 2022: $26.41 million | Q3 2022: $19.68 million | Q1 2023: $52.10 million | Q2 2023: $27.39 million | Q3 2023: $33.82 million | Q1 2024: $30.65 million | Q2 2024: $36.26 million | Q3 2024: $35.51 million | Q1 2025: $41.46 million | Q2 2025: $61.03 million | Q3 2025: $41.97 million.
- Over the full 6 years of available data (2020 to 2025), Cullinan Therapeutics, Inc.'s Research And Development Expense has grown by 333.7%.
- Historical annual values: Fiscal year 2025: $187.40 million | Fiscal year 2024: $142.90 million | Fiscal year 2023: $148.16 million | Fiscal year 2022: $91.95 million | Fiscal year 2021: $57.75 million | Fiscal year 2020: $43.21 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: